Genzyme Launches Renvela(R) in the U.S. for Dialysi... ( Pursues Additional Approvals Glob...)

Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients

Date:3/6/2008

Pursues Additional Approvals Globally for Dialysis and Earlier Stage

Chronic Kidney Disease Patients

CAMBRIDGE, Mass., March 6 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) today announced the U.S. launch of the phosphate binder Renvela(R) (sevelamer carbonate) for dialysis patients, as well as significant progress in its international efforts to secure additional approvals for the product.

Genzyme has submitted a marketing authorization application to the European Medicines Agency seeking approval of Renvela for the control of serum phosphorus in chronic kidney disease patients regardless of whether they are on dialysis. This application, which includes both tablet and powder formulations, must be validated before it will be accepted for review.

Genzyme anticipates that the application will be validated by the end of this month, and the review period is expected to take approximately 15 months. The first E.U. launch of Renvela is anticipated in the third quarter of 2009. Genzyme also applied for approval of Renvela tablets for dialysis patients in the key South American market of Brazil late last year, and will continue to pursue additional approvals internationally.

In the United States, Genzyme is engaged in active discussions with the Food and Drug Administration to expand Renvela's labeling to include chronic kidney disease patients with hyperphosphatemia who are not on dialysis. At the FDA's request, the three companies that currently market phosphate binders for dialysis patients are working collaboratively to provide information that will assist the agency in defining the appropriate earlier stage chronic kidney disease patient population.

Genzyme had previously a
'/>"/>

1

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
2. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
3. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
4. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
5. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
6. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
7. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
8. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
9. Genzyme Launches Cholestagel(R) in Europe
10. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
11. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease

Post Your Comments:

Genzyme Launches Renvela(R) in the U.S. for Dialysi...( Pursues Additional Approvals Glob...)